Table 4

The nine principal components in scaled phenotypic space.

Principal Component

1

2

3

4

5

6

7

8

9


Ritonavir

0.39

0.35

0.60

-0.16

0.30

-0.37

-0.32

-0.05

-0.07


Nelfinavir

0.36

0.33

0.22

-0.05

-0.10

0.31

0.75

-0.11

0.17


Atazanavir

0.39

0.12

-0.10

0.23

0.01

0.72

-0.49

-0.12

-0.04


Amprenavir

0.36

-0.29

-0.17

-0.49

0.29

0.13

0.07

0.63

-0.12


Indinavir

0.33

0.04

-0.14

-0.02

-0.62

-0.23

0.02

-0.02

-0.65


Lopinavir

0.31

-0.12

-0.18

-0.33

-0.43

-0.19

-0.21

-0.15

0.67


Saquinavir

0.38

0.15

-0.48

0.58

0.29

-0.38

0.11

0.14

0.14


Tipranavir

0.23

-0.71

0.48

0.43

-0.12

-0.02

0.07

0.07

0.07


Darunavir

0.19

-0.37

-0.21

-0.23

0.39

-0.04

0.12

-0.72

-0.21


Percent Variance (%)

83.7

6.0

3.1

2.7

1.6

1.0

1.0

0.6

0.3


The first two principal components together capture approximately 90% of the variance in the data and represent development of high resistance toward all drugs and development of high resistance to NFV and RTV with increasing resistance toward ATV, SQV and IDV, respectively.

Doherty et al. BMC Bioinformatics 2011 12:477   doi:10.1186/1471-2105-12-477

Open Data